vs

Side-by-side financial comparison of California Resources Corp (CRC) and MEDIFAST INC (MED). Click either name above to swap in a different company.

California Resources Corp is the larger business by last-quarter revenue ($119.0M vs $75.1M, roughly 1.6× MEDIFAST INC). MEDIFAST INC produced more free cash flow last quarter ($-6.6M vs $-32.0M). Over the past eight quarters, MEDIFAST INC's revenue compounded faster (-34.4% CAGR vs -46.3%).

California Resources Corporation is an American energy corporation engaged in hydrocarbon exploration in California. It is organized in Delaware and headquartered in Long Beach, California. Its mineral acreage holdings in California constitute the largest privately held position in the state.

Medifast, Inc. is an American nutrition and weight loss company based in Baltimore, Maryland. Medifast produces, distributes, and sells weight loss and health-related products through websites, multi-level marketing, telemarketing, and franchised weight loss clinics.

CRC vs MED — Head-to-Head

Bigger by revenue
CRC
CRC
1.6× larger
CRC
$119.0M
$75.1M
MED
More free cash flow
MED
MED
$25.4M more FCF
MED
$-6.6M
$-32.0M
CRC
Faster 2-yr revenue CAGR
MED
MED
Annualised
MED
-34.4%
-46.3%
CRC

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
CRC
CRC
MED
MED
Revenue
$119.0M
$75.1M
Net Profit
Gross Margin
69.4%
Operating Margin
-597.5%
-10.4%
Net Margin
Revenue YoY
-36.9%
Net Profit YoY
EPS (diluted)
$-8.02
$-1.64

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CRC
CRC
MED
MED
Q1 26
$119.0M
Q4 25
$679.0M
$75.1M
Q3 25
$715.0M
$89.4M
Q2 25
$702.0M
$105.6M
Q1 25
$814.0M
$115.7M
Q4 24
$826.0M
$119.0M
Q3 24
$870.0M
$140.2M
Q2 24
$412.0M
$168.6M
Net Profit
CRC
CRC
MED
MED
Q1 26
Q4 25
$12.0M
Q3 25
$64.0M
$-2.3M
Q2 25
$172.0M
$2.5M
Q1 25
$115.0M
$-772.0K
Q4 24
$33.0M
Q3 24
$345.0M
$1.1M
Q2 24
$8.0M
$-8.2M
Gross Margin
CRC
CRC
MED
MED
Q1 26
Q4 25
69.4%
Q3 25
69.5%
Q2 25
72.6%
Q1 25
72.8%
Q4 24
74.1%
Q3 24
75.4%
Q2 24
73.2%
Operating Margin
CRC
CRC
MED
MED
Q1 26
-597.5%
Q4 25
6.9%
-10.4%
Q3 25
13.7%
-4.6%
Q2 25
38.0%
-1.0%
Q1 25
22.9%
-1.1%
Q4 24
8.2%
0.6%
Q3 24
59.5%
1.5%
Q2 24
9.2%
-4.7%
Net Margin
CRC
CRC
MED
MED
Q1 26
Q4 25
1.8%
Q3 25
9.0%
-2.5%
Q2 25
24.5%
2.3%
Q1 25
14.1%
-0.7%
Q4 24
4.0%
Q3 24
39.7%
0.8%
Q2 24
1.9%
-4.8%
EPS (diluted)
CRC
CRC
MED
MED
Q1 26
$-8.02
Q4 25
$0.21
$-1.64
Q3 25
$0.76
$-0.21
Q2 25
$1.92
$0.22
Q1 25
$1.26
$-0.07
Q4 24
$0.87
$0.08
Q3 24
$3.78
$0.10
Q2 24
$0.11
$-0.75

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CRC
CRC
MED
MED
Cash + ST InvestmentsLiquidity on hand
$167.3M
Total DebtLower is stronger
Stockholders' EquityBook value
$2.9B
$198.9M
Total Assets
$248.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CRC
CRC
MED
MED
Q1 26
Q4 25
$132.0M
$167.3M
Q3 25
$196.0M
$173.5M
Q2 25
$72.0M
$162.7M
Q1 25
$214.0M
$164.6M
Q4 24
$372.0M
$162.3M
Q3 24
$241.0M
$170.0M
Q2 24
$1.0B
$163.5M
Total Debt
CRC
CRC
MED
MED
Q1 26
Q4 25
Q3 25
$1.0B
Q2 25
$1.0B
Q1 25
$1.0B
Q4 24
$1.1B
Q3 24
$1.1B
Q2 24
$1.2B
Stockholders' Equity
CRC
CRC
MED
MED
Q1 26
$2.9B
Q4 25
$3.7B
$198.9M
Q3 25
$3.4B
$214.7M
Q2 25
$3.4B
$216.0M
Q1 25
$3.5B
$211.0M
Q4 24
$3.5B
$210.1M
Q3 24
$3.5B
$207.3M
Q2 24
$2.1B
$205.3M
Total Assets
CRC
CRC
MED
MED
Q1 26
Q4 25
$7.4B
$248.0M
Q3 25
$6.8B
$268.2M
Q2 25
$6.7B
$269.3M
Q1 25
$6.8B
$280.0M
Q4 24
$7.1B
$284.2M
Q3 24
$7.1B
$291.2M
Q2 24
$4.5B
$293.5M
Debt / Equity
CRC
CRC
MED
MED
Q1 26
Q4 25
Q3 25
0.29×
Q2 25
0.30×
Q1 25
0.29×
Q4 24
0.32×
Q3 24
0.32×
Q2 24
0.57×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CRC
CRC
MED
MED
Operating Cash FlowLast quarter
$99.0M
$-5.3M
Free Cash FlowOCF − Capex
$-32.0M
$-6.6M
FCF MarginFCF / Revenue
-26.9%
-8.8%
Capex IntensityCapex / Revenue
1.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$380.0M
$1.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CRC
CRC
MED
MED
Q1 26
$99.0M
Q4 25
$235.0M
$-5.3M
Q3 25
$279.0M
$12.1M
Q2 25
$165.0M
$-3.4M
Q1 25
$186.0M
$3.4M
Q4 24
$206.0M
$-4.9M
Q3 24
$220.0M
$9.1M
Q2 24
$97.0M
$13.1M
Free Cash Flow
CRC
CRC
MED
MED
Q1 26
$-32.0M
Q4 25
$115.0M
$-6.6M
Q3 25
$188.0M
$10.8M
Q2 25
$109.0M
$-4.8M
Q1 25
$131.0M
$1.9M
Q4 24
$118.0M
$-7.2M
Q3 24
$141.0M
$7.7M
Q2 24
$63.0M
$11.1M
FCF Margin
CRC
CRC
MED
MED
Q1 26
-26.9%
Q4 25
16.9%
-8.8%
Q3 25
26.3%
12.0%
Q2 25
15.5%
-4.5%
Q1 25
16.1%
1.6%
Q4 24
14.3%
-6.1%
Q3 24
16.2%
5.5%
Q2 24
15.3%
6.6%
Capex Intensity
CRC
CRC
MED
MED
Q1 26
Q4 25
17.7%
1.8%
Q3 25
12.7%
1.5%
Q2 25
8.0%
1.3%
Q1 25
6.8%
1.3%
Q4 24
10.7%
1.9%
Q3 24
9.1%
1.0%
Q2 24
8.3%
1.1%
Cash Conversion
CRC
CRC
MED
MED
Q1 26
Q4 25
19.58×
Q3 25
4.36×
Q2 25
0.96×
-1.36×
Q1 25
1.62×
Q4 24
6.24×
Q3 24
0.64×
8.04×
Q2 24
12.13×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons